Chronic Myeloid Leukemia (CML) Clinical Trial
Official title:
A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs)
The purpose of this study is to assess the safety and efficacy of ponatinib in Japanese patients with chronic myeloid leukemia (CML) who have experienced failure of dasatinib or nilotinib or with Ph+ acute lymphoblastic leukemia (ALL) following failure of prior tyrosine kinase inhibitors (TKIs).
This multi-center, phase 1/2, open-label study will consist of two phases. The first will be a dose escalation phase employing a modified 3+3 design with two dose cohorts (30mg and 45mg). After 6 patients complete the first cycle in a cohort, safety events will be evaluated before opening the next dose cohort. Patients will continue on treatment as long as it is tolerated and disease progression has not occurred. Phase 2 will occur at the recommended dose determined in phase 1 in an additional 25 patients. Another 3 patients will be dosed at 15mg for collection of pharmacokinetic data. These patients may also escalate to the recommended dose and be assessed for efficacy and safety as phase 2 patients. Efficacy measures include molecular, cytogenetic, and hematologic response rates at various time points; time to response; duration of response; and survival follow-up. Safety measures include routine physical and laboratory evaluations, adverse event monitoring, and ECGs. Other measures include mutation testing and molecular genetic assessment. Accrual is expected to take approximately 12 months, and patients will be followed for survival for up to 60 months from the last dose of study drug; therefore, the estimated duration of the trial is 72 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01066468 -
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
|
Phase 1 | |
| Completed |
NCT00428909 -
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
|
Phase 1 | |
| Completed |
NCT04126707 -
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
|
Phase 1 | |
| Active, not recruiting |
NCT02061800 -
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
|
Phase 1/Phase 2 | |
| Completed |
NCT00488592 -
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
|
Phase 2 | |
| Terminated |
NCT03615105 -
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
|
Phase 2 | |
| Recruiting |
NCT02790515 -
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03849651 -
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT02363868 -
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
|
N/A | |
| Withdrawn |
NCT01605981 -
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.
|
Phase 4 | |
| Completed |
NCT00433745 -
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
|
Phase 2 | |
| Not yet recruiting |
NCT04709731 -
Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT03481868 -
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
|
N/A | |
| Recruiting |
NCT02889003 -
Second STOP After Pioglitazone Priming in CML Patients
|
Phase 2 | |
| Completed |
NCT02733445 -
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
|
N/A | |
| Active, not recruiting |
NCT03746054 -
Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality
|
Phase 3 | |
| Completed |
NCT00720785 -
Natural Killer Cells and Bortezomib to Treat Cancer
|
Phase 1 | |
| Recruiting |
NCT05963061 -
Chronic Myeloid Leukemia (CML) Real-Life Database
|
||
| Approved for marketing |
NCT01592136 -
Expanded Access Program of Ponatinib
|
N/A |